Full data set of Amarin REDUCE-IT trial will be presented at AHA in less than 2 weeks. Until then, all we know is that they achieved ~25% RRR in 5-point MACE with a strong p-value of <0.001. Until we see the break down of the individual MACE components it is too early to judge as stellar or not stellar.

BTW, market cap is a better measure to use to compare Resverlogix and Amarin. Amarin went from just below 1 billion USD market cap before top-line data to over 6 billion USD market cap today. For Resverlogix to have a 6 billion market cap the RVXCF share price would be ~30 USD per share.

One big difference is that Amarin’s REDUCE-IT trial was on everyone's radar. Resverlogix's BETonMACE still isn't getting much buzz. My hope is that once the unofficial 250 events are reached and dosing ends, that this represents the turning point for the media coverage/buzz for Resverlogix, apabetalone and BETonMACE.

BearDownAZ